Millennium Management LLC Buys 26,449 Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN)

Millennium Management LLC increased its holdings in Enliven Therapeutics, Inc. (NASDAQ:ELVN - Free Report) by 108.6% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 50,804 shares of the company's stock after buying an additional 26,449 shares during the quarter. Millennium Management LLC owned 0.10% of Enliven Therapeutics worth $1,143,000 at the end of the most recent reporting period.

Several other large investors also recently added to or reduced their stakes in the business. Tower Research Capital LLC TRC boosted its stake in shares of Enliven Therapeutics by 230.2% during the 4th quarter. Tower Research Capital LLC TRC now owns 1,598 shares of the company's stock worth $36,000 after acquiring an additional 1,114 shares during the last quarter. KLP Kapitalforvaltning AS bought a new position in Enliven Therapeutics in the 4th quarter worth $97,000. BNP Paribas Financial Markets purchased a new position in Enliven Therapeutics during the fourth quarter valued at $112,000. ExodusPoint Capital Management LP bought a new stake in Enliven Therapeutics during the fourth quarter valued at about $200,000. Finally, Brevan Howard Capital Management LP purchased a new stake in Enliven Therapeutics in the fourth quarter worth about $228,000. 95.08% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of analysts have recently issued reports on the stock. HC Wainwright increased their price objective on shares of Enliven Therapeutics from $39.00 to $40.00 and gave the stock a "buy" rating in a research note on Thursday, May 15th. Jones Trading dropped their target price on shares of Enliven Therapeutics from $36.00 to $27.00 and set a "buy" rating for the company in a report on Friday, May 16th. Four research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, Enliven Therapeutics presently has an average rating of "Buy" and a consensus target price of $37.25.

Insider Activity

In related news, CEO Samuel Kintz sold 5,000 shares of the business's stock in a transaction on Thursday, April 17th. The stock was sold at an average price of $16.42, for a total transaction of $82,100.00. Following the completion of the transaction, the chief executive officer now owns 985,392 shares in the company, valued at $16,180,136.64. The trade was a 0.50% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Benjamin Hohl sold 3,250 shares of the stock in a transaction on Thursday, March 27th. The stock was sold at an average price of $21.33, for a total value of $69,322.50. Following the completion of the sale, the chief financial officer now owns 23,000 shares in the company, valued at approximately $490,590. The trade was a 12.38% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 94,444 shares of company stock valued at $1,801,057. 29.20% of the stock is currently owned by insiders.

Enliven Therapeutics Stock Performance

Shares of ELVN traded down $0.63 during mid-day trading on Friday, hitting $20.74. 663,450 shares of the stock were exchanged, compared to its average volume of 269,163. The firm has a 50-day moving average of $18.05 and a two-hundred day moving average of $20.85. The company has a market cap of $1.02 billion, a PE ratio of -10.92 and a beta of 1.07. Enliven Therapeutics, Inc. has a 52-week low of $13.30 and a 52-week high of $30.03.

Enliven Therapeutics (NASDAQ:ELVN - Get Free Report) last issued its quarterly earnings data on Wednesday, May 14th. The company reported ($0.57) earnings per share for the quarter, missing the consensus estimate of ($0.51) by ($0.06). On average, sell-side analysts predict that Enliven Therapeutics, Inc. will post -1.95 EPS for the current year.

Enliven Therapeutics Profile

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.